Stock 4174 OBI PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Funds and ETFs OBI Pharma, Inc.

Equities

4174

TW0004174008

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 23:00:00 13/05/2024 BST 		5-day change 1st Jan Change
61.3 TWD +0.16% Intraday chart for OBI Pharma, Inc. 0.00% -11.67%
05-10 Obi Pharma, Inc. Announces the Termination of License Agreement with Odeon for the Rights of Obi-999 and Obi-833 in China, Hong Kong and Macau CI
03-26 OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

ETFs positioned on OBI Pharma, Inc.

Name Weight AuM 1st Jan change Investor Rating
SIMPLIFY EMERGING MARKETS PLUS DOWNSIDE CONVEXITY ETF - USD ETF Simplify Emerging Markets Plus Downside Convexity ETF - USD
0.01% 4 M€ -4.41% -
LEADERSHARES EQUITY SKEW ETF - USD ETF LeaderShares Equity Skew ETF - USD
0.00% 112 M€ +4.57% -
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR ETF Vanguard LifeStrategy 80% Equity UCITS ETF - Distributing - EUR
0.00% 34 M€ +8.28% -
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR ETF Vanguard LifeStrategy 80% Equity UCITS ETF Acc - EUR
0.00% 391 M€ +8.36% -
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - DISTRIBUTING - EUR ETF Vanguard LifeStrategy 60% Equity UCITS ETF - Distributing - EUR
0.00% 39 M€ +5.65% -
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - ACC - EUR ETF Vanguard LifeStrategy 60% Equity UCITS ETF - Acc - EUR
0.00% 306 M€ +5.71% -
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +3.39% -
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF ACC - EUR ETF Vanguard LifeStrategy 40% Equity UCITS ETF Acc - EUR
0.00% 105 M€ +3.32% -
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF ACC - EUR ETF Vanguard LifeStrategy 20% Equity UCITS ETF Acc - EUR
0.00% 54 M€ +0.39% -

Company Profile

OBI Pharma, Inc. is a Taiwan-based company principally engaged in the development of new pharmaceuticals. The Company mainly operates its businesses through the research and development of novel cancer and infectious disease therapies. It also develops next generation active immunotherapies to treat cancers, including lung, prostate, pancreatic, stomach and ovarian cancers. It is engaged in the development of OBI-822 (formerly OPT-822/821), an active immunotherapy new drug for metastatic breast cancer; the research and development of therapeutic vaccine OBI-833 for the treatment of new generation of cancers, as well as the development of cancer testing reagent OBI-868.
Sector
Biotechnology & Medical Research
Calendar
07/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
OBI PHARMA, INC. Stock OBI Pharma, Inc.
-11.67% 433M
MODERNA, INC. Stock Moderna, Inc.
+29.43% 48.16B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.26% 41.73B
LONZA GROUP AG Stock Lonza Group AG
+43.45% 41.03B
CELLTRION, INC. Stock Celltrion, Inc.
-5.26% 28.77B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.10% 25.59B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.95% 18.96B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+7.87% 12.92B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.14% 12.03B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.94% 11.77B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 4174 Stock
  4. Funds and ETFs OBI Pharma, Inc.